Cheapest Place to Buy Sildenafil UK

6. A different version of sildenafil also exists
Choosing between Viagra and sildenafil
To buy male enhancement pills online is a matter of trust
How does the online consultation work?
Buy Viagra Tablets Online in Great Yarmouth
More about sildenafil
Frequently Asked Question

It is characterised by a progressive increase of pulmonary vascular resistance, leading to right ventricular heart failure and premature death. PAH can occur with no identifiable cause. This was previously referred to as primary pulmonary hypertension (PPH) but was renamed as idiopathic PAH (IPAH). PAH is also commonly associated with various conditions including connective tissue disease (CTD-APAH) and congenital heart disease (CHD). Symptoms of PAH include dyspnoea (breathlessness), fatigue, chest pain, syncope (fainting) and oedema, which can result in loss of capacity to perform exercise and eventually activity of daily living.

6. A different version of sildenafil also exists

Further data were obtained from dossiers submitted to the National Institute for Health and Clinical Excellence (NICE) by the manufacturers of the technologies. RCTs of longer than one week duration that compared any of the five technologies (alone or in combination) to placebo, supportive care, any other technologies (alone or in combination) and/or non-licensed drugs in adult PAH patients were included. Inclusion decisions, quality assessment and data extraction were undertaken according to predefined criteria. Where sufficient data were available, meta-analyses were undertaken for each technology using a random effects model. Primary analysis included data from FCIII patients (and FCIV patients for epoprostenol) for licensed doses only.

Levitra Professional

A systematic review of published studies on the costs and cost-effectiveness of the technologies in PAH, and a review of the dossiers submitted to NICE by the manufacturers of the technologies were undertaken. In addition, model-based economic evaluations of the cost-effectiveness of the technologies from the perspective of the UK National Health Service (NHS) and Personal Social Service (PSS) were carried out. A total of 20 RCTs, most of good quality, were included in this assessment. The majority had durations of 12 to 18 weeks and compared one of the technologies added to supportive treatment versus supportive treatment alone. Only a small number of trials compared the technologies against each other or investigated the use of combinations of technologies. It therefore has a devastating impact on both the quality and duration of patients' life. PAH is a rare disease with an estimated incidence of two to four cases per million per year, which approximates 100 to 200 new cases in England and Wales per year. Until the 1990s, PAH was managed by supportive treatments, which include anticoagulation therapy, diuretics, oxygen and digoxin that mainly aim at controlling symptoms. In addition, calcium channel blockers (CCBs) were found to be effective for treating a small proportion of patients with PAH. More recently, new technologies specifically licensed for treating PAH have become available in the UK. These include intravenous epoprostenol, inhaled iloprost, and three oral treatments: bosentan, sitaxentan and sildenafil. The licenses differ between the technologies in terms of type of PAH and severity of disease measured by functional class (FC). These technologies are believed to not only relieve symptoms but also to potentially modify disease progress. Once initiated the technologies are given repeatedly and only when inevitably the disease progresses are additional treatments or (more rarely) switching considered. The costs for these technologies vary but are very high (≈£12–£400 per patient per day, list price of drug only). The objectives of the assessment report were: To assess as far as available data from randomised controlled trials (RCTs) would allow, whether the five technologies named above (alone or in combination) are clinically effective when used within their licensed indications for the treatment of adults with PAH for whom CCBs are inappropriate or no longer effective compared to supportive treatment (and/or intravenous iloprost), and whether the clinical effectiveness differs significantly between PAH of various causes. To assess whether the clinical effectiveness differs significantly between the technologies (alone or in combination) if head-to-head RCTs exist. To assess whether each of the five technologies are cost-effective when used within their licensed indications for treating adults with PAH for whom CCBs are inappropriate or no longer effective compared to supportive treatment. A systematic review of RCTs was undertaken.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	25mg	60 + 4 Pills	71.99€ 68.56€
Viagra Generic	150mg	120 + 8 Pills	177.58€ 169.12€
Viagra Generic	150mg	270 + 10 Pills	326.61€ 311.06€
Viagra Generic	25mg	270 + 8 Pills	184.26€ 175.49€
Kamagra	100mg	60 + 4 Pills	201.34€ 191.75€
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€
Kamagra Polo	100mg	12 Pills	60.21€ 57.34€
Kamagra Soft Tabs	100mg	32 Pills	120.11€ 114.39€
Kamagra Soft Tabs	100mg	12 Pills	57.55€ 54.81€
Kamagra Soft Tabs	100mg	120 + 6 Pills	311.78€ 296.93€
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€

Databases searched included the Cochrane Library, MEDLINE, and EMBASE along with other sources up to February 2007. Further data were obtained from dossiers submitted to the National Institute for Health and Clinical Excellence (NICE) by the manufacturers of the technologies. RCTs of longer than one week duration that compared any of the five technologies (alone or in combination) to placebo, supportive care, any other technologies (alone or in combination) and/or non-licensed drugs in adult PAH patients were included. Inclusion decisions, quality assessment and data extraction were undertaken according to predefined criteria. Where sufficient data were available, meta-analyses were undertaken for each technology using a random effects model.

Choosing between Viagra and sildenafil

How long will it last?

It therefore has a devastating impact on both the quality and duration of patients' life. PAH is a rare disease with an estimated incidence of two to four cases per million per year, which approximates 100 to 200 new cases in England and Wales per year. Until the 1990s, PAH was managed by supportive treatments, which include anticoagulation therapy, diuretics, oxygen and digoxin that mainly aim at controlling symptoms. In addition, calcium channel blockers (CCBs) were found to be effective for treating a small proportion of patients with PAH. More recently, new technologies specifically licensed for treating PAH have become available in the UK. Primary analysis included data from FCIII patients (and FCIV patients for epoprostenol) for licensed doses only. A systematic review of published studies on the costs and cost-effectiveness of the technologies in PAH, and a review of the dossiers submitted to NICE by the manufacturers of the technologies were undertaken. In addition, model-based economic evaluations of the cost-effectiveness of the technologies from the perspective of the UK National Health Service (NHS) and Personal Social Service (PSS) were carried out. A total of 20 RCTs, most of good quality, were included in this assessment. The majority had durations of 12 to 18 weeks and compared one of the technologies added to supportive treatment versus supportive treatment alone.

Pack Size	Price for 50mg Sildenafil (£)	Cost per Tablet (£)	Savings Compared to Single Pack
10 Tablets	£18	£1.80	N/A
20 Tablets	£34	£1.70	£4 per 20 tablets saved
30 Tablets	£48	£1.60	£12 total saved
60 Tablets	£90	£1.50	£30 total saved

Only a small number of trials compared the technologies against each other or investigated the use of combinations of technologies. Many of the trials included patient populations (in terms of FC and types of PAH) and doses that were outside the licensed indication of the technologies. Only very limited data examining specific types (subcategories) of PAH were available. Existing data do not suggest significant differences 200mg sildenafil citrate in treatment effects between subcategories of PAH, but studies are likely to be under-powered to detect clinically important differences.

To buy male enhancement pills online is a matter of trust

Independent economic evaluation gave ICERs for the reference case for epoprostenol plus supportive care compared to supportive care alone of £277,000/quality-adjusted life-year (QALY) for FCIII and £343,000/QALY for FCIV patients. In non-reference case analyses the lowest of these ICERs became £106,000/QALY and £96,000/QALY respectively when the manufacturer's reduced price was used. Most other non-reference case analyses did not appreciably alter the magnitude of the reference case ICERs. The effectiveness of inhaled iloprost has been shown in one double-blind RCT that included patients of mixed FC (III and IV) with mixed types of pulmonary hypertension including non-PAH. For FCIII PPH patients (licensed indication), stratifed data for 6MWD were not available and OR for deterioration in FC at 12 weeks was 0.29 (0.07 to to 1.18) compared to supportive care.

Review of economic evaluations submitted by manufacturers

An additional open-label RCT demonstrated effectiveness in only some of the measured outcomes. Independent economic evaluation gave an ICER for the reference case for iloprost plus supportive care compared to supportive care alone of £101,000/QALY. Non-reference case analyses did not appreciably reduce the magnitude of this ICER. The effectiveness of bosentan was demonstrated in double-blind RCTs that included patients predominantly of FC III and an additional open-label RCT. Effectiveness has been shown in mixed populations of IPAH, CTD-APAH and PAH associated with Eisenmenger syndrome, a specific type of CHD. Data stratified by FC were scant, as such an assessment of treatment effects stratified by FC could not be reliably conducted with the available evidence.

Year	Average Cost per 50mg Tablet (£)	Notes
2023	£2.20	Slight increase due to supply chain issues
2024	£2.00	Prices stabilizing, generic options becoming cheaper
2024	Average Price for 30 Tablets	£60
2024	Best Deal Found	£1.50 per tablet in bulk packs

This is particularly problematic when findings from the clinical effectiveness review were to be used to inform the economic modelling. All the technologies, when added to supportive treatment at their licensed doses, have been shown to be more effective than supportive treatment alone in improving exercise capacity, symptoms of PAH and haemodynamic measures. The volume of evidence and patient populations included in the trials varied between technologies. The incremental cost-effectiveness ratio (ICER) for each technology added to supportive treatment compared to supportive treatment varies considerably between the technologies according to the independent economic evaluation conducted for this report.

How does the online consultation work?

Interactions and contraindications

A double-blind RCT showed no benefit for using the combination of bosentan plus epoprostenol compared to epoprostenol alone in patients of mixed FC (III and IV) with mixed types of PAH (IPAH, CTD-APAH). The effectiveness of intravenous epoprostenol has been shown in open-label RCTs that included both patients with PPH and patients with scleroderma. Pooled results for PPH patients with mixed FC (mainly III & IV, licensed indication) for improvement in 6-minute walk distance (6MWD) was 58 metres (95% confidence interval 6 to 110) and the odds ratio (OR) for FC deterioration at 12 weeks was 0.40 (0.13 to 1.20) compared to supportive care. Independent economic evaluation gave ICERs for the reference case for epoprostenol plus supportive care compared to supportive care alone of £277,000/quality-adjusted life-year (QALY) for FCIII and £343,000/QALY for FCIV patients. In non-reference case analyses the lowest of these ICERs became £106,000/QALY and £96,000/QALY respectively when the manufacturer's reduced price was used. Most other non-reference case analyses did not appreciably alter the magnitude of the reference case ICERs. The effectiveness of inhaled iloprost has been shown in one double-blind RCT that included patients of mixed FC (III and IV) with mixed types of pulmonary hypertension including non-PAH.

Some UK pharmacies offer sildenafil in combination packs for convenience.
Online reviews can help find affordable sildenafil sources in the UK.
The cost of sildenafil can be impacted by pharmacist markup.
Price comparisons should include shipping costs for online UK orders.
Generic sildenafil is generally more affordable in the UK than the brand.
Price ranges for sildenafil in the UK can vary by region.
Many UK online pharmacies require a prescription to sell sildenafil.
Prices for sildenafil in the UK may change due to demand shifts.
Check for authorized sellers to avoid counterfeit sildenafil in the UK.
Some clinics in the UK offer sildenafil at subsidized rates.
Discount codes can sometimes be applied to reduce sildenafil costs.

For FCIII PPH patients (licensed indication), stratifed data for 6MWD were not available and OR for deterioration in FC at 12 weeks was 0.29 (0.07 to to 1.18) compared to supportive care. An additional open-label RCT demonstrated effectiveness in only some of the measured outcomes.

Prices for sildenafil in UK can be significantly reduced with online deals.
Some UK pharmacies sell sildenafil at lower prices during sales events.
The cost greatly depends on whether the sildenafil is branded or generic.
UK purchasing regulations require prescriptions, affecting pricing options.
Price comparison websites help find the best sildenafil deals in the UK.
Many UK clinics provide sildenafil as part of ED treatment packages.
Buying from authorized UK pharmacies prevents counterfeit medications.
UK consumers have access to affordable generic sildenafil options.
The price for sildenafil in the UK may differ based on dosage.
Bulk purchases may qualify for free delivery in the UK.
Price consistency is maintained across licensed UK pharmacies.

Independent economic evaluation gave an ICER for the reference case for iloprost plus supportive care compared to supportive care alone of £101,000/QALY.

Buy Viagra Tablets Online in Great Yarmouth

For FCIII patients with mixed PAH (licensed indication), the pooled result for improvement in 6MWD was 59 metres (20 to 99) and the pooled OR for deterioration in FC at 12 weeks was 0.21 (0.03 to 1.76) compared to supportive care. Independent economic evaluation gave an ICER for the reference case for bosentan plus supportive care compared to supportive care alone of £27,000/QALY. Non-reference case analysis demonstrated the ICER was sensitive to running the model over a shorter time horizon and with a lower cost of epoprostenol. The effectiveness of sitaxentan was demonstrated in double-blind RCTs that included patients of mixed FC (predominantly II and III) with mixed PAH (IPAH, CTD-APAH and PAH associated with CHD). For FCIII patients with mixed PAH (licensed indication), no stratified data for improvement in 6MWD were available and the pooled OR for deterioration in FC at 12 weeks was 0.18 (0.02 to 1.64) compared to supportive care.

Is there a difference between Viagra and Sildenafil?

Independent economic evaluation gave an ICER for the reference case for sitaxentan plus supportive care compared to supportive care of £25,000/QALY. The effectiveness of sildenafil was demonstrated in a double-blind RCT that included patients of mixed FC (predominantly II and III) with mixed PAH (IPAH, CTD-APAH and PAH associated with CHD). For FCIII patients with mixed PAH (licensed indication), no stratified data for improvement in 6MWD were available and the OR for deterioration in FC at 12 weeks was [confidential information removed] compared to supportive care. Independent economic evaluation demonstrated that for the most part sildenafil plus supportive care was more effective and less costly than supportive care alone and therefore dominated supportive care. Even when sildenafil did not dominate ICERs were on the whole still relatively low. Non-reference case analyses did not appreciably reduce the magnitude of this ICER. The effectiveness of bosentan was demonstrated in double-blind RCTs that included patients predominantly of FC III and an additional open-label RCT.

More about sildenafil

Many of the trials included patient populations (in terms of FC and types of PAH) and doses that were outside the licensed indication of the technologies. Only very limited data examining specific types (subcategories) of PAH were available. Existing data do not suggest significant differences 200mg sildenafil citrate in treatment effects between subcategories of PAH, but studies are likely to be under-powered to detect clinically important differences. Data stratified by FC were scant, as such an assessment of treatment effects stratified by FC could not be reliably conducted with the available evidence. This is particularly problematic when findings from the clinical effectiveness review were to be used to inform the economic modelling.

Direct comparison

All the technologies, when added to supportive treatment at their licensed doses, have been shown to be more effective than supportive treatment alone in improving exercise capacity, symptoms of PAH and haemodynamic measures. The volume of evidence and patient populations included in the trials varied between technologies. The incremental cost-effectiveness ratio (ICER) for each technology added to supportive treatment compared to supportive treatment varies considerably between the technologies according to the independent economic evaluation conducted for this report. The effectiveness of intravenous epoprostenol has been shown in open-label RCTs that included both patients with PPH and patients with scleroderma. Pooled results for PPH patients with mixed FC (mainly III & IV, licensed indication) for improvement in 6-minute walk distance (6MWD) was 58 metres (95% confidence interval 6 to 110) and the odds ratio (OR) for FC deterioration at 12 weeks was 0.40 (0.13 to 1.20) compared to supportive care. Effectiveness has been shown in mixed populations of IPAH, CTD-APAH and PAH associated with Eisenmenger syndrome, a specific type of CHD. For FCIII patients with mixed PAH (licensed indication), the pooled result for improvement in 6MWD was 59 metres (20 to 99) and the pooled OR for deterioration in FC at 12 weeks was 0.21 (0.03 to 1.76) compared to supportive care. Independent economic evaluation gave an ICER for the reference case for bosentan plus supportive care compared to supportive care alone of £27,000/QALY. Non-reference case analysis demonstrated the ICER was sensitive to running the model over a shorter time horizon and with a lower cost of epoprostenol. The effectiveness of sitaxentan was demonstrated in double-blind RCTs that included patients of mixed FC (predominantly II and III) with mixed PAH (IPAH, CTD-APAH and PAH associated with CHD). For FCIII patients with mixed PAH (licensed indication), no stratified data for improvement in 6MWD were available and the pooled OR for deterioration in FC at 12 weeks was 0.18 (0.02 to 1.64) compared to supportive care. Independent economic evaluation gave an ICER for the reference case for sitaxentan plus supportive care compared to supportive care of £25,000/QALY. The effectiveness of sildenafil was demonstrated in a double-blind RCT that included patients of mixed FC (predominantly II and III) with mixed PAH (IPAH, CTD-APAH and PAH associated with CHD). For FCIII patients with mixed PAH (licensed indication), no stratified data for improvement in 6MWD were available and the OR for deterioration in FC at 12 weeks was [confidential information removed] compared to supportive care.

The average cost of sildenafil in UK pharmacies is around £15-£35 per pack.
Online UK pharmacies often provide sildenafil at reduced prices.
Price comparisons are essential for best deals on sildenafil.
In the UK, sildenafil costs vary by seller and dosage strength.
Legal regulations influence sildenafil pricing in the UK market.
Discounts are sometimes available for regular sildenafil buyers in the UK.
Buying from licensed UK pharmacies guarantees product authenticity.
Prices for sildenafil can depend on geographic location within the UK.
Special offers sometimes include sildenafil with other ED medications.
Bulk purchasing may reduce the overall unit cost in the UK.
Price differences can be significant between UK and international sources.

Independent economic evaluation demonstrated that for the most part sildenafil plus supportive care was more effective and less costly than supportive care alone and therefore dominated supportive care.

Frequently Asked Question

These include intravenous epoprostenol, inhaled iloprost, and three oral treatments: bosentan, sitaxentan and sildenafil. The licenses differ between the technologies in terms of type of PAH and severity of disease measured by functional class (FC). These technologies are believed to not only relieve symptoms but also to potentially modify disease progress. Once initiated the technologies are given repeatedly and only when inevitably the disease progresses are additional treatments or (more rarely) switching considered. The costs for these technologies vary but are very high (≈£12–£400 per patient per day, list price of drug only).

Kamagra Fizzy Tabs

The objectives of the assessment report were: To assess as far as available data from randomised controlled trials (RCTs) would allow, whether the five technologies named above (alone or in combination) are clinically effective when used within their licensed indications for the treatment of adults with PAH for whom CCBs are inappropriate or no longer effective compared to supportive treatment (and/or intravenous iloprost), and whether the clinical effectiveness differs significantly between PAH of various causes. To assess whether the clinical effectiveness differs significantly between the technologies (alone or in combination) if head-to-head RCTs exist. To assess whether each of the five technologies are cost-effective when used within their licensed indications for treating adults with PAH for whom CCBs are inappropriate or no longer effective compared to supportive treatment. A systematic review of RCTs was undertaken. Databases searched included the Cochrane Library, MEDLINE, and EMBASE along with other sources up to February 2007. Even when sildenafil did not dominate ICERs were on the whole still relatively low.

Brand Name	Average Cost per 50mg Tablet (£)	Generic Available	Manufacturer
Viagra	£2.50	Yes	Pfizer
Sildenafil UK	£1.80	Yes	Local Pharma
Revatio	£3.20	Yes	Pfizer
Kamagra	£1.50	Yes	Ajanta Pharma

Only two RCTs have directly compared the technologies against each other. No significant difference between the technologies was observed in any outcome in both trials. However, the conclusion was limited by small sample size in one trial and differential blinding of treatments in the other trial. No independent economic analysis was undertaken for this comparison. Use of the combinations of the technologies was investigated in four RCTs. A double-blind RCT showed no benefit for using the combination of bosentan plus epoprostenol compared to epoprostenol alone in patients of mixed FC (III and IV) with mixed types of PAH (IPAH, CTD-APAH).